In vitro assessment of combined antibiotic and mucolytic treatment for Pseudomonas aeruginosa infection in cystic fibrosis.
The minimal inhibitory concentration of azlocillin for Pseudomonas aeruginosa is appreciably reduced when combined with the mucolytic agent mesna (Mistabron) because of an independent bacteriostatic effect of mesna. Bactericidal activity of azlocillin is unaltered by mesna. Mesna inhalations alone or combined with azlocillin may benefit cystic fibrosis patients with pseudomonas lung infections.
D001390:Azlocillin; D003550:Cystic Fibrosis / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D008623:Mercaptoethanol / Q000031:analogs & derivatives*; D015080:Mesna / Q000008:administration & dosage / Q000627:therapeutic use*; D010406:Penicillins / Q000008:administration & dosage / Q000627:therapeutic use*; D011552:Pseudomonas Infections / Q000188:drug therapy*
D010406:Penicillins; D008623:Mercaptoethanol; D001390:Azlocillin; D015080:Mesna